HomeNewsBusinessMarketsIndia looks expensive with downgraded earnings; underweight on IT, pharma: JPMorgan

India looks expensive with downgraded earnings; underweight on IT, pharma: JPMorgan

Adrian Mowat, JPMorgan is underweight on IT, pharma and consumer staples due to expensive valuations. He likes private players in the financial space

August 22, 2017 / 19:21 IST
Story continues below Advertisement

Your browser doesn't support HTML5 video.

"US equity market is looking comparatively vulnerable while we are neutral on emerging markets," Adrian Mowat, JPMorgan said in an interview to CNBC-TV18.

He feels India is an expensive market with downgraded earnings. Emerging markets saw FIIs outflow in August, including India, but domestic money continued to support India.

Story continues below Advertisement

According to him, if there is no pick up in earnings and economic growth and slowdown in domestic inflows, then there could be a deep correction in the market because valuations are stretched.

He is underweight on IT, pharma and consumer staples due to expensive valuations. He likes private players in the financial space.